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Median canaliform nail dystrophy is an unusual condition 
of the nail, most often affecting the thumb (1). It is cha-
racterized by a longitudinal split or canal in the nail with 
small transversal fissures, in a fir-tree configuration. The 
condition is diagnosed based on its clinical features (2, 3). 
While the underlying mechanism is unknown, it has been 
suggested that median canaliform nail dystrophy is the 
result of a temporary defect in the nail matrix, following 
dyskeratinization or focal infection, or alternatively is due 
to self-inflicted trauma to the nail or nail bed. Familial 
cases have been reported (2, 3). Spontaneous remission 
is often seen, but the condition can be recurrent (1).
Three case reports of median canaliform nail dys-
trophy as an adverse effect of acne treatment with 
isotretinoin (13-cis-retinoic acid) have been published 
(3–5). Alitretinoin (9-cis-retinoic acid), on the other 
hand, is used in the treatment of severe chronic hand 
eczema (6–8). We report here a case of median canali-
form nail dystrophy that developed in a patient treated 
with alitretinoin for severe hand eczema.
CASE REPORT
A 53-year-old man, with a history of chronic dyshidrotic and 
keratotic hand and foot eczema, developed nail changes after 
receiving alitretinoin treatment for 16 months. The changes 
were most prominent on the thumbnails, where he presented 
median longitudinal ridging and splitting with transversal fis-
sures. There were both horizontal and fir-tree shaped fissures 
among the transversal changes. Minor nail plate dystrophy was 
seen on the other nails, and all nails on both hands had ragged 
cuticles and enlarged lunulae. 
The patient’s eczema was diagnosed in 1998 and initial treat-
ment with topical and systemic steroids, azathioprine, metho-
trexate, acitretin, cyclosporine or mycophenolate mofetil had 
either adverse effects or worked insufficiently. In 2008, alitreti-
noin became available on the Danish market and it was prescribed 
to the patient in 2009. He initially received 30 mg daily, but deve-
loped adverse effects, such as headache, vertigo and universal dry 
skin with pruritus, after less than 1 month’s treatment. A reduction 
in the dose was tried, first to 30 mg every third day, and later to 
10 mg daily, but the adverse effects remained and the treatment 
was discontinued after 6 months. In 2012, the patient’s eczema 
worsened and alitretinoin was reintroduced at a daily dose of 10 
mg. After being treated with alitretinoin for 16 months, the patient 
developed the characteristic nail findings, which were diagnosed 
as median canaliform nail dystrophy (Fig. 1A). The patient had 
no personal or family history of nail diseases. He denied self-
inflicted trauma to the nail. The nail folds were neither red nor 
swollen, but the cuticles on all fingers were retracted and torn, 
which they had been since the onset of his hand eczema. The 
patient had enlarged lunulae on all nails. This condition did not 
disappear after the discontinuation of alitretinoin. He did not 
receive other medications known to interact with alitretinoin 
and he had normal blood tests apart from slightly elevated lipids. 
Alitretinoin was discontinued, and follow-up visits after 3 and 
6 months documented outgrowth of normal nail on both thumbs 
(Fig. 1B and 1C). At present the patient is being treated with 
cyclosporine, 150 mg daily, and his hand eczema is in remission.
DISCUSSION 
The pathogenesis of median canaliform nail dystrophy 
is unknown, but it is believed to be caused by a dys-
keratotic reaction in a predisposed individual (4, 5). 
Idiopathic cases are most often self-healing, but when 
persistent, excision of the nail matrix abnormality can 
be tried. When caused by medication, the treatment is 
discontinuation of the suspected drug.
In the reported cases of isotretinoin-induced median 
canaliform nail dystrophy, nail changes occurred after 
6–8 weeks, and attenuated when treatment was discon-
tinued (3–5). Alitretinoin, like other licensed retinoids, 
affects cell formation, cell differentiation, keratiniza-
tion, apoptosis and immune regulation, and therefore, 
adverse effects could be expected to be similar to those 
of isotretinoin (7). Several adverse effects have been 
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Fig. 1. (A) Median nail dystrophy 
of both thumbs after 16 months’ 
treatment with alitretinoin and 
outgrowth of normal nails (B) 3 
months and (C) 6 months after 
discontinuation of treatment.
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described for alitretinoin, such as headache, blushing, 
elevated blood lipids, hypothyroidism, depression, and 
dryness of the skin and lips (7, 8). As the drug is rela-
tively new, reports of novel adverse effects, especially 
of long-term treatment, may be expected. 
In this case, the nail changes occurred after approx-
imately 16 months of treatment, and the patient had not 
developed median canaliform nail dystrophy during 
his previous alitretinoin treatment period of 6 months. 
The longitudinal nail ridges support the patient’s claim 
that changes were not self-inflicted, as self-inflicted 
trauma most often causes transverse changes (2). It 
was deemed improbable that the nail changes were 
caused by the patient’s chronic hand eczema, as he had 
not experienced similar changes in the 15 years since 
diagnosis. Alitretinoin treatment was discontinued after 
the nail changes were discovered, and follow-up visits 
after 3 and 6 months demonstrated outgrowth of normal 
nails on both thumbs. While idiopathic cases of median 
canaliform nail dystrophy can go into spontaneous re-
mission, the immediate discontinuation response makes 
it unlikely in this patient. 
In conclusion, we suggest that median canaliform nail 
dystrophy is an adverse effect of long-term treatment 
with alitretinoin, which may limit the usefulness of this 
drug in the treatment of chronic hand eczema.
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